Pan-RAF inhibitor active in melanomas that are resistant to BRAF or BRAF /MEK inhibitor combinations.
Session type: Parallel sessions
The protein kinase BRAF is mutated ~40% of human melanomas. BRAF is a component of the RAS/RAF/MEK/ERK pathway and BRAF or MEK inhibitors increase progression-free and overall survival in melanoma patients with BRAF mutations. However, most patients relapse with acquired resistance and ~20% of patients present intrinsic resistance and do not respond to these drugs.